ARTBIO Inc.
ARTBIO is a clinical-stage company developing a new class of alpha radioligand therapies (ART) using the alpha-emitting Pb212, which delivers powerful, short-lived bursts of energy into tumors for greater efficacy than other isotopes. ARTBIO's proprietary Alpha-DirectTM technology enables Pb212 production in a distributed manufacturing network that delivers its pipeline to patients. AB001 enters the clinic for prostate cancer in 2025; 3 additional programs advance quickly.
Date, time and room information
May 6, 12:45 - 13:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Unleashing the power of Alpha Radioligand Therapy (ART)
Speaker information
| Name | Position | Institution |
|---|---|---|
| Emanuele Ostuni | CEO | ARTBIO Inc. |
